Adult Immunizations

Öz

Protection from infectious diseases is the first and easiest method. Therefore, immunization against vaccine-preventable infectious diseases is as important in adulthood as it is during childhood. Although immunization is generally accepted as a practice specific to childhood both worldwide and in our country, it continues throughout life. With adult immunization, the incidence of vaccine-preventable infectious diseases is reduced, and mortality and healthcare costs are significantly decreased. Despite efforts to raise awareness, adult vaccination rates are still not at ideal levels. Most adults do not know which vaccines they need. Many groups, such as individuals with comorbidities, the elderly, healthcare workers, and international travelers, can protect many lives by getting vaccinated. In line with the recommendations of the Expanded Immunization Program implemented by the World Health Organization, many vaccine-preventable infectious diseases have reached the point of elimination. In recent years, adult immunization has gained importance within the scope of preventive medicine, and immunization strategies are being reconsidered. The goal of the Life-Long Immunization strategy is to prevent adult morbidity and mortality, reduce treatment costs, and minimize workforce losses. The aim of this review is to examine the current literature, immunization recommendations, and practices for adult age groups.

Anahtar Kelimeler

• Keywords: Adult
• Immunization
• Vaccination

Erişkin Bağışıklama

Öz

Enfeksiyon hastalıklarından korunma, ilk ve en kolay yoldur. Bu sebeple, aşı ile önlenebilir enfeksiyon hastalıklarında bağışıklama çocukluk döneminde olduğu kadar erişkin yaş grupları içinde önem taşımaktadır. Dünyada ve ülkemizde immünizasyon genellikle çocukluk dönemine özgü bir uygulama olarak kabul edilmesine rağmen yaşam boyu devam etmektedir. Erişkin bağışıklama ile aşı ile önlenebilir enfeksiyon hastalıklarında hastalık insidansı düşürülmekte, mortalite ve sağlık harcamaları önemli oranda azaltılmaktadır. Arttırılmaya çalışılan farkındalığa rağmen erişkin bağışıklama düzeyleri halen ideal seviyelerde değildir. Erişkinlerin çoğu kendileri için gerekli olan aşıları bilmemektedir. Komorbiditeleri olan bireyler, yaşlılar, sağlık çalışanları, uluslararası seyahat edenler gibi birçok grup aşılanarak pek çok yaşamın korunmasını sağlayabilir. Dünya Sağlık Örgütü tarafından uygulanan Genişletilmiş Bağışıklama Programı önerileri doğrultusunda birçok aşı ile önlenebilir enfeksiyon hastalıkları eliminasyon noktasına gelmiştir. Koruyucu hekimlik kapsamında erişkin yaşta bağışıklama son yıllarda önem kazanmakta, bağışıklama stratejileri yeniden gözden geçirilmektedir. Yaşam Boyu Bağışıklama stratejisi ile erişkin morbidite ve mortalitenin önlenmesi, tedavi maliyetleri ve iş gücü kayıplarının azaltılması hedeflenmektedir. Bu derlemede amaç, erişkin yaş gruplarında güncel literatürü, bağışıklama önerilerini ve uygulamaları incelemektir.

Anahtar Kelimeler

• Erişkin
• İmmünizasyon
• Bağışıklama

Kaynakça

1. 1. Plotkin S. History of vaccination. Proceedings of the National Academy of Sciences U S A. 2014;111(34):12283-12287.doi:10.1073/pnas.1400472111.
2. 2. Leung AKC. “Variolation” and Vaccination in Late Imperial China, Ca 1570–1911. In: Plotkin SA,ed. History of Vaccine Development. Springer; 2011:5-12. doi:10.1007/978-1-4419-1339-5_2.
3. 3. Canouï E, Launay O. [History and principles of vaccination]. La Revue des Maladies Respiratoires2019;36(1):74-81.doi:10.1016/j.rmr.2018.02.015.
4. 4. Aşı Portalı. Accessed August 20, 2024. https://asi.saglik.gov.tr/asi/
5. 5. Velipaşaoğlu S. Aşı İmmünitesi ve Yanıtını Etkileyen Faktörler. Osmangazi Tıp Dergisi. Published online March 23, 2020:1-5. doi:10.20515/otd.676787.
6. 6. Geckin B, Konstantin Föhse F, et al. Trained immunity: implications for vaccination. Current Opinion in Immunology. 2022;77:102190. doi:10.1016/j.coi.2022.102190.
7. 7. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394-397. doi:10.1038/41131.
8. 8. D’Amico C, Fontana F, Cheng R, et al. Development of vaccine formulations: past, present, and future. Drug Delivery and Translational Research. 2021;11(2):353-372. doi:10.1007/s13346-021-00924-7.

9. 9. https://covid19asi.saglik.gov.tr/TR-77805/asi-turleri.html.
10. 10. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines.Nature Biotechnology. 2010;28(6):573-579. doi:10.1038/nbt.1635.
11. 11. Hansson M, Nygren PA, Ståhl S. Design and production of recombinant subunit vaccines. Biotechnology and Applied Biochemistry. 2000;32(2):95-107. doi:10.1042/ba20000034.
12. 12. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Frontiers in immunology. 2019;10:594. doi:10.3389/fimmu.2019.00594.
13. 13. Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020;368(6486):14-16.doi:10.1126/science.368.6486.14.
14. 14. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology. 2021;21(2):83-100. doi:10.1038/s41577-020-00479-7.
15. 15. Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. The New England Journal of Medicine2018;379(17):1621-1634. doi:10.1056/NEJMoa1803484.
16. 16. von Reyn CF, Lahey T, Arbeit RD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS One. 2017;12(5):e0175215. doi:10.1371/journal.pone.0175215.
17. 17. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/malaria.
18. 18. Zencirci SA, Metintaş S. Sıtma aşılarındaki gelişmeler. ESTÜDAM Halk Sağlığı Dergisi 2017;2(1), 32-38.
19. 19. Genton B. R21/Matrix-MTM malaria vaccine: a new tool to achieve WHO’s goal to eliminate malaria in 30 countries by 2030? The Journal of Travel Medicine. 2023;30(8):taad140. doi:10.1093/jtm/taad140
20. 20. Tan L. Adult vaccination: Now is the time to realize an unfulfilled potential. Human Vaccines & Immunotherapeutics. 2015;11(9):2158-2166. doi:10.4161/21645515.2014.982998.
21. 21. Gözdemir E, Kaygusuz İ. Gebelikte Tetanoz Aşısı. Gaziosmanpaşa Tıp Dergisi. 2014;6(3):159-167.
22. 22. Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. The Morbidity and Mortality Weekly Report (MMWR). 2020;69(3):77-83. doi:10.15585/mmwr.mm6903a5.
23. 23. Sağlık Hizmetleri Daire Başkanlığı. Accessed August 26, 2024.https://khgmsaglikhizmetleridb.saglik.gov.tr/TR-42863/yara-yonetiminde-tetanoz-proflaksisemasi.html
24. 24. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hall E., Wodi A.P., Hamborsky J., et al., eds. 14th ed. Washington, D.C. Public Health Foundation, 2021.
25. 25. Genişletilmiş Bağışıklama Programı Genelgesi. Accessed August 21, 2024. https://www.saglik.gov.tr/TR-11080/genisletilmis-bagisiklama-programi-genelgesi.html
26. 26. Kızamık Eliminasyon programı Erişim tarihi: Accessed August 21, 2024. https://hsgm.saglik.gov.tr/depo/Mevzuat/Genel_Nitelikli_Yazi_ve_Gorusler/Kizamik_Eliminasyon_Programi.pdf.
27. 27. Ma SJ, Li X, Xiong YQ, et al. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. Medicine (Baltimore). 2015;94(44):e1721. doi:10.1097/MD.0000000000001721.
28. 28. Murthy N, Wodi AP, McNally VV, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States,2024. The Morbidity and Mortality Weekly Report (MMWR). 2024;73(1):11-15. doi:10.15585/mmwr.mm7301a3.
29. 29. Ahmed SS, Pondo T, Xing W, et al. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States. Clinical Infectious Diseases. 2020;70(12):2484-2492. doi:10.1093/cid/ciz739.
30. 30. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. The Morbidity and Mortality Weekly Report (MMWR). 2022;71(4):109-117. doi:10.15585/mmwr.mm7104a1.
31. 31. van de Sandt CE, Kreijtz JHCM, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 2012;4(9):1438-1476. doi:10.3390/v4091438.
32. 32. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. The MMWR Recommendations and Reports. 2023;72. doi:10.15585/mmwr.rr7202a1.
33. 33. Monto AS, Zambon M, Weir JP. The End of B/Yamagata Influenza Transmission – Transitioning from Quadrivalent Vaccines. The New England Journal of Medicine. 2024;390(14):1256-1258. doi:10.1056/NEJMp2314801.
34. 34. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season. The MMWR Recommendations and Reports. 2022;71(1):1-28. doi:10.15585/mmwr.rr7101a1.
35. 35. CDC. CDC Seasonal Flu Vaccine Effectiveness Studies. Flu Vaccines Work. August 8, 2024. Accessed August 26, 2024. https://www.cdc.gov/flu-vaccines-work/php/effectiveness-studies/index.html
36. 36. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). The MMWR Recommendations and Reports. 2011;60(2):1-64.
37. 37. Dilek M, Helvacı M, Aksu N. Evaluation of Varicella Complications. The Turkish Journal of Biochemistry. 2015;4(4):360-365. doi:10.5505/abantmedj.2015.67699.
38. 38. Marin M, Marti M, Kambhampati A, et al. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 2016;137(3):e20153741. doi:10.1542/peds.2015-3741.
39. 39. Rafferty E, Reifferscheid L, Russell ML, et al. The impact of varicella vaccination on paediatric herpes zoster epidemiology: a Canadian population-based retrospective cohort study. European Journal of Clinical Microbiology & Infectious Diseases. 2021;40(11):2363-2370.doi:10.1007/s10096-021-04298-z.
40. 40. Macartney K, Heywood A, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database of Systematic Reviews 2014;2014(6):CD001833.doi:10.1002/14651858.CD001833.pub3
41. 41. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. The Journal of infectious diseases. 2010;201(7):1024-1030.doi:10.1086/651199.
42. 42. Cunningham AL, Heineman TC, Lal H, et al. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. The Journal of infectious diseases.2018;217(11):1750-1760.doi:10.1093/infdis/jiy095.
43. 43. Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. The Morbidity and Mortality Weekly Report (MMWR). 2022;71(3):80-84. doi:10.15585/mmwr.mm7103a2.
44. 44. Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. The Morbidity and Mortality Weekly Report MMWR). 2019;68(4):91-94. doi:10.15585/mmwr.mm6804a4.
45. 45. Charkoudian LD, Kaiser GM,Steinmetz RL, Srivastava SK. Acute retinal necrosis after herpes zoster vaccination. Archives of ophthalmology. 2011;129(11):1495-1497. doi:10.1001/archophthalmol.2011.320.
46. 46. Ödemiş İ, Köse Ş, Gireniz Tatar B, et al. Hepatitis A, B, C and HIV seroprevalence among young health care workers: A cross-sectional study. Journal of Dr. Behcet Uz Children's Hospital. Published online 2018. doi:10.5222/buchd.2018.008.
47. 47. Aslan S, Şahin A, Doğantekin E, et al. Gaziantep İlindeki Hepatit A Seroprevalansı ve Endemik Değişim. Harran Üniversitesi Tıp Fakültesi Dergisi.2024;21(1):113-117. doi:10.35440/hutfd.1423081.
48. 48. Foster MA, Hofmeister MG, Albertson JP, et al. Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018. The Morbidity and Mortality Weekly Report (MMWR).2021;70(24):875-878. doi:10.15585/mmwr.mm7024a2.
49. 49. Wang XY, Xu ZY, Ma JC, et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine. 2007;25(3):446 449.doi:10.1016/j.vaccine.2006.08.004.
50. 50. Brennan J, Moore K, Sizemore L, et al. Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018. Morbidity and Mortality Weekly Report (MMWR). 2019;68(14):328-329. doi:10.15585/mmwr.mm6814a3.
51. 51. Hepatitis B. Accessed August 20, 2024. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
52. 52. Türkiye Viral Hepatit Önleme Ve Kontrol Programı 2018-2023. Ankara: Sağlık Bakanlığı Yayın No: 1102, 2018 https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf.
53. 53. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. The MMWR Recommendations and Reports. 2018;67(1):1-31. doi:10.15585/mmwr.rr6701a1.
54. 54. CDC. Responding to HBV Exposures in Health Care Settings. Hepatitis B. May 16, 2024. Accessed August 26, 2024. https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html.
55. 55. Tekin S, Karakeçili F, Binay U, et al. Management of Chronic Hepatitis B in Special Patient Groups:A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023. Klimik Dergisi/Klimik Journal. 2023;36:23-42.doi:10.36519/kd.2023.4684.
56. 56. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology.Methods in Molecular Biology. 2012;799:1-20. doi:10.1007/978-1-61779-346-2_1.
57. 57. Kizil MC, Kilic O, Ceyhan M, et al. Nasopharyngeal Meningococcal Carriage among Children and Adolescents in Turkey in 2018: An Unexpected High Serogroup X Carriage. Children (Basel).2021;8(10):871. doi:10.3390/children8100871.
58. 58. Tekin RT, Dinleyici EC, Ceyhan M, et al. The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey. Human Vaccines&Immunotherapeutics.2017;13(5):1182-1189. doi:10.1080/21645515.2016.1268304.
59. 59. Yardımcı B, İneli B, Akdeniz M. Erişkinlerde Aşılama. Aile Hekimliği. 2016;8(2):29-47.
60. 60. St Geme JW, Takala A, Esko E, et al. Evidence for capsule gene sequences among pharyngeal isolates of nontypeable Haemophilus influenzae. The Journal of Infectious Diseases. 1994;169(2):337-342.doi:10.1093/infdis/169.2.337.
61. 61. Haemophilus influenzae Tip b (Hib) Hastalığı. Accessed August 19, 2024. https://asi.saglik.gov.tr/asi/liste/5-haemophilus-influenzae-tip-b-hib-hastal%C4%B1%C4%9F%C4%B1-nedir.html
62. 62. Tezer H. Dünyada Polio’da Son Durum. Journal of Pediatric Infection. 2017;11(1):60-60. doi:10.5578/ced.201704.
63. 63. Kidd S, Clark T, Routh J, et al. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices -United States, 2023. The Morbidity and Mortality Weekly Report (MMWR). 2023;72(49):1327-1330.doi:10.15585/mmwr.mm7249a3.
64. 64. HPV Vaccination Recommendations | CDC. May 22, 2023. Accessed August 20, 2024. https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html
65. 65. Ageing | United Nations. Accessed August 22, 2024. https://www.un.org/en/global-issues/ageing